VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist Vicenç Torrente-Segarra, Asunción Acosta Pereira, Rosa Morla, José Miguel Ruiz, Teresa Clavaguera, Ramon Figuls, Hector Corominas, Carme Geli, Rosa Roselló, Juan José de Agustín, Cayetano Alegre, Carolina Pérez, Angel García, Arturo Rodríguez de la Serna

Primary Tuberculosis Infection in Patients Treated With Tumor Necrosis Factor-alpha Antagonists and a Negative Initial Screening José Antonio Bernal, Mariano Andrés, Vega Jovaní, Raquel García Sevila, Alejandra Begazo, Paloma Vela

Cutaneous lupus erythematosus induced by the treatment with tumor necrosis factor antagonists Walter Alberto Sifuentes Giraldo, María Ahijón Lana, Mónica Vázquez Díaz